Geode Capital Management LLC Has $7.25 Million Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Geode Capital Management LLC increased its position in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 14.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,043,864 shares of the company's stock after acquiring an additional 129,600 shares during the quarter. Geode Capital Management LLC owned 1.98% of Zevra Therapeutics worth $7,246,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. International Assets Investment Management LLC boosted its position in shares of Zevra Therapeutics by 594.0% in the third quarter. International Assets Investment Management LLC now owns 6,940 shares of the company's stock worth $48,000 after buying an additional 5,940 shares during the period. Hunter Associates Investment Management LLC acquired a new stake in Zevra Therapeutics during the 3rd quarter worth about $92,000. XTX Topco Ltd purchased a new position in Zevra Therapeutics during the 3rd quarter valued at about $94,000. Intech Investment Management LLC acquired a new position in shares of Zevra Therapeutics in the 3rd quarter valued at about $95,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Zevra Therapeutics during the third quarter worth approximately $105,000. Hedge funds and other institutional investors own 35.03% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Canaccord Genuity Group decreased their target price on shares of Zevra Therapeutics from $25.00 to $23.00 and set a "buy" rating for the company in a research note on Thursday, November 14th. Roth Mkm boosted their price target on Zevra Therapeutics from $19.00 to $21.00 and gave the company a "buy" rating in a research note on Tuesday, September 24th. Maxim Group raised their price objective on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the company a "buy" rating in a research report on Tuesday, September 24th. JMP Securities started coverage on shares of Zevra Therapeutics in a research note on Tuesday, September 24th. They issued an "outperform" rating and a $17.00 target price for the company. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Zevra Therapeutics in a research note on Friday, October 11th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $21.00.

Zevra Therapeutics Stock Performance

Shares of NASDAQ ZVRA traded down $0.17 during trading hours on Friday, hitting $8.59. 394,003 shares of the company's stock were exchanged, compared to its average volume of 396,651. The stock has a market capitalization of $458.50 million, a price-to-earnings ratio of -4.36 and a beta of 1.97. The company's 50-day moving average price is $8.77 and its 200-day moving average price is $7.48. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88. Zevra Therapeutics, Inc. has a 1-year low of $4.20 and a 1-year high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.25). The firm had revenue of $3.70 million for the quarter, compared to analyst estimates of $5.04 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. During the same period last year, the business earned ($0.40) earnings per share. On average, sell-side analysts expect that Zevra Therapeutics, Inc. will post -1.96 earnings per share for the current fiscal year.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.